🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04916197
Recruiting Phase 4

Effect of Postoperative Prolonged Sedation With Dexmedetomidine After Successful Reperfusion With EVT on Long-term Prognosis in Patients With AIS (PPDET)

NCT04916197 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Chao Yang Hospital
Phase
Phase 4
Started
2024-03-01
Last updated
2023-12-20

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

Dexmedetomidine prolonged sedation0.9% saline

Dexmedetomidine prolonged sedation: Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.

0.9% saline: An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.

Study summary

Dexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury. The investigators hypothesized that the prolonged sedation of dexmedetomidine after successful reperfusion of endovascular thrombectomy may improve the clinical outcome of acute ischemic stroke patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * 2≤NIHSS≤25 * mRS score before stroke was less than 3 * Acute ischemic stroke (including anterior circulation) * mTICI rate 2b or 3 * According to the 2018 AHA/ASA guidelines for the management of acute ischemic stroke, patients who plan to receive mechanical thrombectomy under local anesthesia and sedation * Informed consent was signed by patient or legal representative Exclusion Criteria: * Intracerebral hemorrhage occurred in the responsible vessel area in the past 6 weeks * Patients who had received stent treatment at the responsible vessel in the past * Neurological function was restored at or before angiography * Patients who are allergic to heparin, aspirin, clopidogrel, rapamycin, lactic acid polymer, poly (n-butyl methacrylate), stainless steel, anesthetics and contrast agents or have contraindications * Hemoglobin was less than 70g/L, platelet count was less than 50×109/L, international normalized ratio (INR) greater than 1.5 (irreversible), there are uncorrectable bleeding factors * Blood glucose \< 2.7 mmol/L or \> 22.2 mmol/L * Severe liver or kidney disfunction, ALT\>3 times the upper limit of normal value or AST\>3 times the upper limit of normal value, creatinine\>1.5 times the upper limit of normal value * Pregnant or lactating women * Previous history of mental illness * Stroke with other acute diseases or postoperative stroke of other operation * Heart rate less than 50bpm, second or third degree of atrioventricular block (except for pacemaker implantation), systolic blood pressure less than 90mmHg (two vasoactive drugs were already infused continuously )

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing ChaoYang Hospital Beijing Beijing Municipality Recruiting

More Beijing Chao Yang Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04916197 on ClinicalTrials.gov ↗ ← All trials in China